Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Estradiol Valerate

FDA-approved product (injectable, injection), marketed as Delestrogen, Estradiol Valerate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Estradiol Valerate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrophic Vaginitis
  • Atrophy
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Dyspareunia
  • Hypogonadism
  • Menopause
  • Menorrhagia
  • Osteoporosis
  • Postmenopausal atrophic vaginitis
  • Postmenopausal osteoporosis
  • Premature ovarian insufficiency
  • Primary ovarian insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Natural and semisynthetic estrogens, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Estradiol Valerate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Estradiol Valerate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

    NCT03959891 · start 2019-05-30

    Registered record
    Registry ID
    NCT03959891
    Conditions
    Breast Cancer
    Interventions
    Ipatasertib; Fulvestrant; Aromatase Inhibitor; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2019-05-30
    Completion
    2027-08
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionIpatasertib; Fulvestrant; Aromatase Inhibitor; Palbociclib
    PhasePhase 1
    Registry statusActive not recruiting

  • SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

    NCT03204318 · start 2017-12-07

    Registered record
    Registry ID
    NCT03204318
    Conditions
    Endometriosis Related Pain
    Interventions
    Relugolix; Estradiol/norethindrone acetate; Estradiol/norethindrone acetate placebo; Relugolix placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-07
    Completion
    2021-04-08
    Enrolment
    638

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis Related Pain
    InterventionRelugolix; Estradiol/norethindrone acetate; Estradiol/norethindrone acetate placebo; Relugolix placebo
    PhasePhase 3
    Registry statusCompleted

  • Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation

    NCT03544762 · start 2017-09-08

    Registered record
    Registry ID
    NCT03544762
    Conditions
    Breast Cancer
    Interventions
    18F-FES PET
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-09-08
    Completion
    2020-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Intervention18F-FES PET
    PhasePhase 3
    Registry statusUnknown

  • GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

    NCT02983604 · start 2017-01-10

    Registered record
    Registry ID
    NCT02983604
    Conditions
    Advanced Estrogen Receptor Positive HER2- Breast Cancer
    Interventions
    GS-5829; Exemestane; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-01-10
    Completion
    2018-07-19
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Estrogen Receptor Positive HER2- Breast Cancer
    InterventionGS-5829; Exemestane; Fulvestrant
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS

    NCT02866786 · start 2016-08-15

    Registered record
    Registry ID
    NCT02866786
    Conditions
    Polycystic Ovary Syndrome
    Interventions
    Metformin; ethinyl estradiol and cyproterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-08-15
    Completion
    2017-08-01
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome
    InterventionMetformin; ethinyl estradiol and cyproterone acetate
    PhasePhase 4
    Registry statusCompleted

  • Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

    NCT02792517 · start 2016-02-12

    Registered record
    Registry ID
    NCT02792517
    Conditions
    Headache, Migraine
    Interventions
    Erenumab; Ethynil Estradiol/Norgestimate Oral Contraceptive
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-12
    Completion
    2016-09-09
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache, Migraine
    InterventionErenumab; Ethynil Estradiol/Norgestimate Oral Contraceptive
    PhasePhase 1
    Registry statusCompleted

  • Endocrine Response in Women With Invasive Lobular Breast Cancer

    NCT02206984 · start 2015-09-30

    Registered record
    Registry ID
    NCT02206984
    Conditions
    Breast Cancer
    Interventions
    Tamoxifen; Anastrozole; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-09-30
    Completion
    2024-07-19
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionTamoxifen; Anastrozole; Fulvestrant
    PhasePhase 2
    Registry statusCompleted

  • LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation

    NCT02449642 · start 2015-07

    Registered record
    Registry ID
    NCT02449642
    Conditions
    Infertility
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-07
    Completion
    2015-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Investigational Oocyte Cryopreservation for Medical and Non Medical Indications

    NCT04616417 · start 2015-05-08

    Registered record
    Registry ID
    NCT04616417
    Conditions
    Infertility, Female; Deferred Childbearing
    Interventions
    Investigational Oocyte Cryopreservation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-05-08
    Completion
    2023-03-20
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Deferred Childbearing
    InterventionInvestigational Oocyte Cryopreservation
    PhaseNot applicable
    Registry statusCompleted

  • Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS

    NCT01909141 · start 2013-08

    Registered record
    Registry ID
    NCT01909141
    Conditions
    Polycystic Ovary Syndrome; Infertility
    Interventions
    induction of ovulation using letrozole-pioglitazone-metformin; induction of ovulation using clomiphene citrate-pioglitazone-metformin; transvaginal ultrasound; body mass index (BMI) calculation; day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone; pretreatment blood urea and serum creatinine; serum estradiol (E2) on day 12; serum progesterone on day 21; blood urea and serum creatinine every month
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2014-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Infertility
    Interventioninduction of ovulation using letrozole-pioglitazone-metformin; induction of ovulation using clomiphene citrate-pioglitazone-metformin; transvaginal ultrasound; body mass index (BMI) calculation +5 more
    PhaseEarly phase 1
    Registry statusCompleted

  • Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT

    NCT01790282 · start 2013-03

    Registered record
    Registry ID
    NCT01790282
    Conditions
    IVF; Infertility
    Interventions
    estradiol plus progesterone 100 mg IM injection; Progesterone IM of 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-03
    Completion
    2015-03
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF; Infertility
    Interventionestradiol plus progesterone 100 mg IM injection; Progesterone IM of 100 mg
    PhaseNot applicable
    Registry statusCompleted

  • Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women

    NCT01633814 · start 2011-09

    Registered record
    Registry ID
    NCT01633814
    Conditions
    Menopause; Aging; Blood Pressure
    Interventions
    Transdermal estradiol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2011-09
    Completion
    2015-08
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Aging; Blood Pressure
    InterventionTransdermal estradiol; Placebo
    PhaseNot applicable
    Registry statusTerminated

  • Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol

    NCT01419353 · start 2011-08

    Registered record
    Registry ID
    NCT01419353
    Conditions
    Infertility
    Interventions
    estradiol valerate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-08
    Completion
    2013-06
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    Interventionestradiol valerate
    PhasePhase 4
    Registry statusCompleted

  • Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer

    NCT01399086 · start 2011-04

    Registered record
    Registry ID
    NCT01399086
    Conditions
    Breast Cancer
    Interventions
    Fulvestrant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-09
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionFulvestrant
    PhaseNot recorded
    Registry statusCompleted

  • Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2

    NCT01221831 · start 2010-09

    Registered record
    Registry ID
    NCT01221831
    Conditions
    Contraception
    Interventions
    estetrol, P 1 and placebo tablets; estetrol, P2 and placebo tablets; Estradiol valerate, dienogest and placebo tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-09
    Completion
    2011-09
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    Interventionestetrol, P 1 and placebo tablets; estetrol, P2 and placebo tablets; Estradiol valerate, dienogest and placebo tablets
    PhasePhase 2
    Registry statusCompleted